A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes (ELDERLY-T)

Study Overview

Primary objective:

  • Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice

Secondary objective:

  • Treatment satisfaction

Study details

Study duration per participant is expected to be approximately 24 weeks

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Type 2 Diabetes Mellitus (T2DM)
  • Age: 75 Years
  • Gender: All

Inclusion Criteria:

  • Type 2 diabetes mellitus (T2DM) with oral antidiabetic drug (OAD) ± Glucagon-like-peptide-1 receptor agonist (GLP-1-RA) ± basal insulin (other than insulin glargine 300 U/ml)
  • Age ≥75 years incl. patients from outpatient and inpatient care forms
  • Glycohaemoglobin (Hba1c) ≥8.0% and ≤11.0%
  • Inadequate glycaemic control (HbA1c), defined by the treating physician
  • Ability and willingness to perform fasting blood glucose (BG) measurements themselves or with the support of third parties
  • Signed consent form

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Age <75 years
  • Contraindications to insulin glargine 300 U/ml
  • Short-acting insulin in medication
  • Current participation in clinical research
  • Life expectancy <1 year
  • Known alcohol or drug abuse
  • Mini Mental State Examination Score ≤19
        The above information is not intended to contain all considerations relevant to a potential
        participation in a clinical trial.

Updated on 12 Apr 2024. Study ID: NCT05607160